business

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Financial Times · Jun 9, 2026, 1:03 AM · Also reported by 2 other sources

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year

Read full story on Financial Times → More top stories

Also covered by

Investing.com GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports Bloomberg Markets GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

Aggregated and edited by the Scoop newsroom. We surface news from Financial Times alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Also covered by

More in business